Beigene entered the stock market in 2016.
Beigene came to the United States in 2015.
“Change is the Cure” is Beigene’s new campaign to promote all of their cancer drugs to the world.
What is beige?
Beigene is a Chinese pharmaceutical company that started in 2010 as a company focused on research and development that over time. To this day, Beigene has a global team on five continents, including more than 1,000 in the United States and hundreds in Europe and Australia.
According to Josh Neiman, chief commercial officer for North America and Europe, at BeiGene, “BeiGene is pleased to work with Ontada to advance our shared vision of improving patient access, affordability and value for healthcare stakeholders. oncology community and key partners working at the intersection of clinical practice and real-world evidence”
“Working together, BeiGene and Ontada will generate novel oncology insights through real-world data, tools and technologies that will facilitate the acceleration of accurate decision-making in support of community oncology practices whose ultimate mission is to improve patient outcomes” , said.
The companies will also seek to drive the use of RWE in healthcare and regulatory decision-making to “increase timely and affordable patient access to life-saving cancer therapies.”
The idea is for companies to highlight the virtues of cancer drugs and their value in order to partially justify their often high price using the RWE.
In recent years, BeiGene has become a big name in cancer drugs and has a growing share of the cancer drug market.
It has three approved drugs, including the BTK inhibitor Brukinsa, which gained FDA approval in the US in 2019, as well as PD-1. the antibody tislelizumab and the PARP inhibitor pamiparib, both approved in China.